We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Residence Time Evaluation of Marketed OTC Ophthalmic Products

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00804791
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : February 2, 2012
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
The objective of this study is to measure ocular surface residence time (in minutes) of two marketed OTC ophthalmic products in dry eye patients.

Condition or disease Intervention/treatment
Dry Eye Other: Systane Ultra Lubricant Eye Drops Other: Unisol 4 Saline Solution

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : November 2008
Primary Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care
Drug Information available for: Systane
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Systane
One drop dispensed into each eye
Other: Systane Ultra Lubricant Eye Drops
artificial tears solution for lubricating the cornea
Active Comparator: Unisol
One drop dispensed into each eye
Other: Unisol 4 Saline Solution
saline solution for irrigating the cornea

Primary Outcome Measures :
  1. Ocular Surface Residence Time [ Time Frame: After 8 minutes, then every 2 minutes ]
    Ocular surface residence time is the time for fluorescent intensity of the cornea to return to baseline measurement after installation of test article.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent and HIPAA read, signed and dated before conducting any procedures.
  • Adult volunteers diagnosed with mild to moderate dry eye. Criteria for diagnosis must include 2 of the 3 following characteristics: composite symptom score > or = to 5 on modified Schein questionnaire; NaFl TFBUT < or = to 7 seconds in either eye; or NaFl corneal staining sum score > or = to 3 (using 0-15 point grading system).
  • Able and willing to follow study instructions. 4) Best-corrected V.A. of 0.6 logMAR or better OU.

Exclusion Criteria:

  • History or evidence of ocular or intraocular surgery in either eye w/i the past 6 months.
  • History or evidence of serious ocular trauma in either eye w/i the past 6 months.
  • History of intolerance or hypersensitivity to any component of the study medications.
  • History or evidence of epithelial herpes simplex keratitis, vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva and/or eyelids, mycobacterial infection of the eye, and/or fungal disease of the eye.
  • Use of concomitant topical ocular medications during the study period.
  • Patients using systemic medications that may contribute to dry eye may not be enrolled unless they have been on a stable dosing regimen for a minimum of 30 days prior to Visit 1, and the dosing regimen must remain stable throughout the study period.
  • Ocular conditions such as conjunctival infections, iritis, or any other ocular condition that may preclude the safe admininstration of the test article.
  • Individuals unwilling to d/c contact lens wear during the study period. CL wear must have been d/c at least one week prior to Visit 1.
  • Participation in an investigational drug or device study w/i 30 days of entering this study.
  • Additionally, any subject may be declared ineligible for a valid medical reason.

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00804791     History of Changes
Other Study ID Numbers: M-08-11
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: February 2, 2012
Last Verified: January 2012

Keywords provided by Alcon Research:
dry eye
residence time

Additional relevant MeSH terms:
Pharmaceutical Solutions
Lubricant Eye Drops
Ophthalmic Solutions